Regenxbio (RGNX) Likely to Surpass Earnings Predictions: Will the Share Price Rise?

Regenxbio (RGNX) Q4 2025 Earnings Preview: What to Expect

Regenxbio (RGNX) is anticipated to report earnings for the quarter ending December 2025 that are in line with the same period last year, despite a notable increase in revenue. While analyst consensus provides a general outlook, the actual results compared to these expectations could significantly influence the stock's short-term movement.

The company is scheduled to announce its earnings on March 5. If Regenxbio surpasses key estimates, the stock could see upward momentum; however, disappointing results may lead to a decline.

Although management’s commentary during the earnings call will play a major role in shaping future expectations and immediate price action, it’s helpful to consider the likelihood of an earnings-per-share (EPS) surprise.

Analyst Consensus and Revenue Outlook

Current projections suggest Regenxbio will post a quarterly loss of $1.01 per share, matching the loss reported in the same quarter last year.

Revenue is forecasted to reach $31.49 million, representing a 48.5% increase year-over-year.

Trends in Estimate Revisions

Over the past month, the consensus EPS estimate for the quarter has remained steady, indicating that analysts have not changed their collective outlook during this period.

It’s important to note that individual analyst revisions may not always be reflected in the overall consensus.

Understanding the Earnings ESP Model

Changes in analyst estimates ahead of earnings releases can provide insight into the company’s business environment. The Zacks Earnings ESP (Expected Surprise Prediction) model is designed to capture this dynamic.

The model compares the Most Accurate Estimate with the Zacks Consensus Estimate for the quarter. Since the Most Accurate Estimate is updated more recently, it may better reflect the latest information available to analysts.

A positive Earnings ESP reading suggests a higher probability that actual results will exceed consensus estimates, especially when paired with a favorable Zacks Rank (#1 Strong Buy, #2 Buy, or #3 Hold). According to Zacks research, this combination has led to positive earnings surprises nearly 70% of the time, and a strong Zacks Rank further enhances the model’s predictive ability.

However, a negative Earnings ESP does not necessarily indicate an earnings miss, and the model is less reliable for stocks with negative ESP readings or lower Zacks Ranks (#4 Sell or #5 Strong Sell).

Regenxbio’s Current Earnings Outlook

For Regenxbio, the Most Accurate Estimate currently exceeds the Zacks Consensus Estimate, indicating that analysts have become more optimistic about the company’s performance. This results in an Earnings ESP of +115.84%.

The stock also holds a Zacks Rank of #3 (Hold), which, when combined with the positive ESP, points to a strong chance of beating consensus EPS expectations.

Reviewing Past Earnings Surprises

Analysts often look at a company’s track record of meeting or exceeding estimates when forecasting future results. For the previous quarter, Regenxbio was expected to report a loss of $1.38 per share but actually posted a smaller loss of $1.20, resulting in a positive surprise of 13.04%.

Over the past four quarters, Regenxbio has outperformed consensus EPS estimates twice.

Key Takeaways

While beating or missing earnings estimates can influence a stock’s direction, other factors may also drive price changes. Some stocks decline even after an earnings beat if other aspects disappoint investors, and some rise despite missing estimates due to unexpected positive developments.

Nonetheless, focusing on companies likely to exceed earnings expectations can improve investment outcomes. Checking a company’s Earnings ESP and Zacks Rank before earnings releases can be a valuable part of your strategy.

Regenxbio appears well-positioned for an earnings beat, but investors should also consider other factors before making investment decisions around the earnings release.

Industry Comparison: Nuvation Bio Inc. (NUVB)

Nuvation Bio Inc. (NUVB), another company in the Zacks Medical - Biomedical and Genetics sector, is projected to report a quarterly loss of $0.11 per share for the period ending December 2025, reflecting a 26.7% improvement from the prior year. Revenue is expected to reach $27.43 million, a substantial 380.4% increase year-over-year.

The consensus EPS estimate for Nuvation Bio has not changed in the past 30 days, but the Most Accurate Estimate is higher, resulting in an Earnings ESP of +25.58%.

With a Zacks Rank of #3 (Hold) and a positive ESP, Nuvation Bio also appears likely to beat consensus EPS estimates. Over the last four quarters, the company has exceeded estimates once.